ADC Therapeutics SA (ADCT) 2022年年度报告「NYSE」.pdf

1、ADC Therapeutics SA2022 Annual ReportTable of ContentsAnnual Report1Table of ContentsLetter to Shareholders3Business Update5Financial Review59Corporate Governance76Report from the Auditor on the Consolidated IFRS Financial Statements91Consolidated IFRS Financial Statements for the Year Ended Decembe

2、r 31,202298Report from the Auditor on the Statutory Financial Statements of ADC Therapeutics SA162Statutory Financial Statements of ADC Therapeutics SA for the Year Ended December 31,2022167Report from the Auditor on the Compensation Report of ADC Therapeutics SA183Compensation Report of ADC Therape

3、utics SA for the Year Ended December 31,2022187Forward Looking Statements199Table of ContentsAnnual Report2DearShareholders,2022wasatransitionalyearforusaswefocusedtheCompanysstrategy,advancedourportfolio,evolvedthemanagementteamandstrengthenedourbalancesheet.Webelievewehavelaidthefoundationtocontin

4、uetogrowandarepoisedforsuccessin2023andbeyond.Theseniorleaderswhojoinedoverthepastfewmonthsareindustryveteranswiththedriveandambitiontohelpmaximizethepotentialofourprolificscienceandindustry-leadingcapabilitiesinthefieldofantibodydrugconjugates.Webelievewearenowwell-positioned to unlock the tremendo

5、us value of the Company through our three core pillars of growth:optimizing theZYNLONTAopportunity,advancingourPBD-basedpipelineandbroadeningourADCplatformandleadership.OptimizingtheZYNLONTAOpportunityWeviewZYNLONTAspotentialinthreehorizons:1)thecurrentlyapprovedindicationinDLBCLinthird-lineorlatert

6、herapy,wherethereremainsahighunmetmedicalneed,2)thenon-systemicchemo-basedcombinationofZYNLONTAwithrituximabinfirst-andsecond-lineDLBCL,and3)novelcombinationsinearlylines.In2022,wemadesignificantstrideseducatingphysiciansaboutZYNLONTAsdifferentiatedprofilewithtargetedinitiativestoincreasethedepthint